Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 1

Editorial ||FREE PAPER||

Authors Garry M Walsh

Published 15 March 2007 Volume 2007:3(1) Pages 1—2

Garry M Walsh

Asthmatic and Allergic Inflammation Group, School of Medicine, University of Aberdeen, UK

This issue of Therapeutics and Clinical Risk Management contains two interesting and thorough review articles on the use of anti-tumor necrosis factor (TNF) monoclonal antibodies (mAb) in the treatment of rheumatoid arthritis and related disorders. The arthritic diseases and distressing conditions associated with significant morbidity are typified by reductions in functional capacity and quality of life with attendant substantial healthcare expenditure. Development of specifically targeted biological agents in recent years has greatly enhanced the therapeutic options for the treatment of the arthritic diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. TNF is an attractive biological target as it has been implicated as a major pro-inflammatory player in a wide range of other conditions, in addition to the arthritic diseases, including inflammatory bowel disease (D’Haens and Daperno 2006), asthma (Cazzola and Polosa 2006), and other autoimmune diseases (Chatzantoni and Mozaki 2006). Levels of TNF are elevated in the relevant sites of inflammation in these conditions; eg, in the synovial fluid and sera of patients with active rheumatoid arthritis. TNF is a potent osteogenic cytokine and is the central mediator of inflammation and joint destruction in rheumatoid arthritis. Three TNF antagonists are currently available: infliximab, a chimeric anti-TNF mAb; adalimumab, a fully human anti-TNF mAb; and etanercept, a recombinant soluble p75 TNF-receptor-Fc fusion protein. Although there are no clinical studies that directly compare etanercept, infliximab, or adalimumab in the treatment of rheumatoid arthritis, data from noncomparative trials suggest that all have similar therapeutic efficacy.

Download Article [PDF] 

Readers of this article also read:

Silencing B7-H1 enhances the anti-tumor effect of bladder cancer antigen-loaded dendritic cell vaccine in vitro

Wang S, Wang YH, Liu J, Shao SX, Li XJ, Gao JN, Niu HT, Wang XS

OncoTargets and Therapy 2014, 7:1389-1396

Published Date: 5 August 2014

The use of nanoencapsulation to decrease human skin irritation caused by capsaicinoids

Contri RV, Frank LA, Kaiser M, Pohlmann AR, Guterres SS

International Journal of Nanomedicine 2014, 9:951-962

Published Date: 12 February 2014

The use of amniotic membrane in trabeculectomy for the treatment of primary open-angle glaucoma: a prospective study

Stavrakas P, Georgopoulos G, Milia M, Papaconstantinou D, Bafa M, Stavrakas E, Moschos M

Clinical Ophthalmology 2012, 6:205-212

Published Date: 2 February 2012

Adult-onset bulbar ptosis in Joubert syndrome

Burt B, Levine J, Le K

Clinical Ophthalmology 2012, 6:151-153

Published Date: 24 January 2012

Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets

Claudio Gasperini, Serena Ruggieri, Carlo Pozzilli

Therapeutics and Clinical Risk Management 2010, 6:391-399

Published Date: 31 August 2010

A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers

Seyed Ali Sadjadi, James I McMillan, Navin Jaipaul, Patricia Blakely, et al.

Therapeutics and Clinical Risk Management 2009, 5:547-552

Published Date: 10 July 2009

The use of amisulpride in the treatment of acute psychosis

Philippe Nuss, Martina Hummer, Cédric Tessier

Therapeutics and Clinical Risk Management 2007, 3:3-11

Published Date: 15 March 2007